Status:
UNKNOWN
Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet
Lead Sponsor:
Bayhealth Medical Center
Conditions:
Weight Loss
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The epidemic of overweight and obese patients presents a major challenge in chronic disease prevention and overall health across the world. Since the beginning of this century, it is considered the th...
Detailed Description
The epidemic of overweight and obese patients presents a major challenge in chronic disease prevention and overall health across the world. Since the beginning of this century, it is considered the th...
Eligibility Criteria
Inclusion
- BMI of 30-35
Exclusion
- Underlying conditions such as hypertension, hyperlipidemia, diabetes, etc.
- BMI out of range listed above
- Inability to participate in an intermittent fasting diet
- Pregnant patients, as rifaximin should be used with caution in pregnancy due to limited data. (Subjects of childbearing age will undergo a baseline pregnancy test prior to starting the study)
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04674176
Start Date
January 1 2021
End Date
January 1 2022
Last Update
December 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayhealth Medical Center- Dover Family Physicians and GI Consultants Office
Dover, Delaware, United States, 19901